Victoria Gray, diagnosed with sickle cell disease as an infant, endured decades of severe pain, hospitalisations and blood transfusions before becoming the first patient to receive an experimental CRISPR treatment in 2019. Doctors edited her stem cells and returned them after chemotherapy, dramatically reducing her pain crises and dependence on transfusions. Her experience helped demonstrate the potential of gene editing and contributed to the development of Casgevy, the first CRISPR-based therapy for sickle cell disease, approved in 2023.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.